Capricor Therapeutics Inc (OTCMKTS:CAPR) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Tuesday.

According to Zacks, “Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. “

Separately, Roth Capital set a $12.00 price target on shares of Capricor Therapeutics and gave the stock a “buy” rating in a report on Thursday, October 20th.

Shares of Capricor Therapeutics (OTCMKTS:CAPR) traded down 0.16% during trading on Tuesday, hitting $3.17. The stock had a trading volume of 7,783 shares. Capricor Therapeutics has a 52 week low of $1.88 and a 52 week high of $5.40. The company’s market capitalization is $56.91 million. The company’s 50 day moving average price is $3.14 and its 200 day moving average price is $3.56.

In related news, major shareholder Sinai Medical Center Cedars bought 312,500 shares of the business’s stock in a transaction that occurred on Wednesday, September 21st. The stock was bought at an average cost of $3.20 per share, for a total transaction of $1,000,000.00. Following the completion of the transaction, the insider now owns 2,904,798 shares of the company’s stock, valued at $9,295,353.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

A number of hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. raised its stake in Capricor Therapeutics by 25.6% in the second quarter. Vanguard Group Inc. now owns 27,975 shares of the company’s stock valued at $111,000 after buying an additional 5,704 shares during the last quarter. Granite Point Capital Management L.P. acquired a new stake in Capricor Therapeutics during the third quarter valued at about $219,000. Finally, LLBH Private Wealth Management LLC raised its stake in Capricor Therapeutics by 4.2% in the third quarter. LLBH Private Wealth Management LLC now owns 124,591 shares of the company’s stock valued at $404,000 after buying an additional 5,000 shares during the last quarter.

ILLEGAL ACTIVITY WARNING: “Capricor Therapeutics Inc (CAPR) Upgraded to Hold by Zacks Investment Research” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another site, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2016/11/22/capricor-therapeutics-inc-capr-upgraded-to-hold-by-zacks-investment-research.html.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications.

Receive News & Stock Ratings for Capricor Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics Inc and related stocks with our FREE daily email newsletter.